Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Emery

Showing results (71-80 of 140) with videos related to

Pageof 14
Sort By:
Journal of Clinical Microbiology|April 19, 2013
Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative studyElise Tu, Luke C Swenson, Sally Land, et al.
AIDS (London, England)|December 20, 2007
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phaseJohn M Murray, Sean Emery, Anthony D Kelleher, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2012
A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adultsDianne Carey, Sarah L Pett, Mark Bloch, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2010
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteersAkil Jackson, Andrew Hill, Rebekah Puls, et al.
AIDS (London, England)|August 8, 2013
Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapyAllison Martin, Cecilia Moore, Patrick W G Mallon, et al.
AIDS (London, England)|July 1, 2010
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patientsAmit C Achhra, Janaki Amin, Matthew G Law, et al.
AIDS (London, England)|April 21, 2004
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension StudyAllison Martin, Don E Smith, Andrew Carr, et al.
Clinical Trials (London, England)|April 12, 2017
Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalizationRoss L Peterson, David M Vock, John H Powers, et al.
AIDS (London, England)|May 23, 2012
Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individualsAmit C Achhra, Janaki Amin, Caroline Sabin, et al.
Plos One|February 28, 2015
Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cARTAlan Winston, Rebekah Puls, Stephen J Kerr, et al.
Pageof 14

Showing results (71-80 of 140) with videos related to

Sort By:
Pageof 14
Journal of Clinical Microbiology|April 19, 2013
Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative studyElise Tu, Luke C Swenson, Sally Land, et al.
AIDS (London, England)|December 20, 2007
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phaseJohn M Murray, Sean Emery, Anthony D Kelleher, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2012
A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adultsDianne Carey, Sarah L Pett, Mark Bloch, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2010
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteersAkil Jackson, Andrew Hill, Rebekah Puls, et al.
AIDS (London, England)|August 8, 2013
Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapyAllison Martin, Cecilia Moore, Patrick W G Mallon, et al.
AIDS (London, England)|July 1, 2010
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patientsAmit C Achhra, Janaki Amin, Matthew G Law, et al.
AIDS (London, England)|April 21, 2004
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension StudyAllison Martin, Don E Smith, Andrew Carr, et al.
Clinical Trials (London, England)|April 12, 2017
Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalizationRoss L Peterson, David M Vock, John H Powers, et al.
AIDS (London, England)|May 23, 2012
Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individualsAmit C Achhra, Janaki Amin, Caroline Sabin, et al.
Plos One|February 28, 2015
Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cARTAlan Winston, Rebekah Puls, Stephen J Kerr, et al.
Pageof 14